In the News
Jakub Tolar, M.D., Ph.D., Transplant Biology and Therapy Program, recently gave a TedXFargo talk about his research and groundbreaking treatment of a serious skin disorder called Epidermolysis Bullosa.
Todd M. Tuttle, M.D., Screening, Prevention, Etiology and Cancer Survivorship Program, was quoted in a KTBS News story about the tripling of double mastectomies for breast cancer tripled the past 10 years.
Daniel A. Vallera, Ph.D., Tumor Microenvironment Program, and Veronika Bachanova, M.D., Ph.D., Transplant Biology and Therapy Program, were featured in a KARE11 “Tackle Cancer” story about how donations and research helped University of Minnesota physics professor, Cynthia Cattell, fight cancer.
Aasma Shaukat, MD,Screening, Prevention, Etiology and Cancer Outcomes (SPECS) Program, was quoted in a Medicine Net story about a new at-home colon cancer test.
Jeffrey Miller, MD, Transplant Biology and Therapy Program, and Daniel Vallera, PhD, Tumor Microenvironment Program, were quoted in reports on Oxis Biotech signing an exclusive license agreement with University of Minnesota to develop and commercialize of its cancer therapies using Trispecific Killer Engager (TriKE) technology.
Dan Knights, PhD, Tumor Microenvironment Program, was mentioned in a Twin Cities Business Magazine story about promising U of M biotech research nearing commercialization.
Yahoo Finance reports that the biotech company Oxis added new patients in Phase 1/Phase 2 clinical trial of a key cancer drug OXS-1550 developed by Daniel Vallera, Ph.D., Tumor Microenvironment Program.
The research of Louis Mansky, PhD, Genetic Mechanisms of Cancer Program, showing that most types of retroviruses have distinct, non-identical virus structures, was featured in several media outlets.
